Stay updated on PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial

Sign up to get notified when there's something new on the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:10:12.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of PDR001 when administered in combination with platinum-doublet chemotherapy and other immunooncology agents in treatment naive patients with PD-L1 unselected, advanced NSCLC.
    Difference
    0.1%
    Check dated 2024-06-06T14:20:42.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 6 has been updated to indicate that the clinical trial for PDR001 in combination with platinum-doublet chemotherapy and other immunology agents in PD-L1 unselected, metastatic NSCLC patients has been terminated due to the competitive landscape for lung cancer therapies. The U.S. government does not review or approve the safety and science of all studies listed on the website, and users are advised to read the full disclaimer for details.
    Difference
    100%
    Check dated 2024-05-22T20:30:23.000Z thumbnail image
  8. Check
    26 days ago
    Change Detected
    Summary
    The value 'Recruitment halted prematurely due to competitive landscape for lung cancer therapies' has been added to the webpage, indicating a significant change in the status of the clinical trial for PD-L1 unselected, metastatic NSCLC patients.
    Difference
    70%
    Check dated 2024-05-21T12:37:47.000Z thumbnail image
  9. Check
    46 days ago
    Change Detected
    Summary
    The value 'Go to the classic website' has been updated to 'Site Map' on the webpage, indicating a change in the type of intervention being highlighted. This change may be related to medical and healthcare-related publications and documentation.
    Difference
    1%
    Check dated 2024-05-01T18:48:50.000Z thumbnail image

Stay in the know with updates to PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page.